Table 2.

Baseline clinical characteristics of group A (current topical therapy + PEA 600 mg one tablet a day, in the first period) and group B (current topical therapy alone, in the first period) (RE = right eye, LE = left eye).

	Overall group (40 patients)		Group A (21 patients)		Group B (19 patients)
	RE	LE	RE	LE	RE	LE
Visual acuity (decimals)	10 [10–10]	10 [9–10]	10 [10–10]	10 [9–10]	10 [10–10]	10 [10–10]
IOP (mmHg)	14.5 [12.5–16]	14.5 [12–16]	14[12–16]	15[12–16]	15 [13–16]	14 [12–16]
Vertical c/d ratio	0.7 [0.6–0.8]	0.7 [0.7–0.8]	0.7 [0.6–0.8]	0.7 [0.7–0.8]	0.7 [0.6–0.8]	0.7 [0.7–0.8]
Visual field
MD (decibels)	− 2.1 [− 4.2 to − 1.2]	− 3.8[− 6.2 to − 1.5]	− 2.2 [− 3.8 to − 1.5]	− 4.1 [− 5.8 to − 0.9]	− 1.9 [− 4.7 to − 1.1]	− 3.7 [− 6.7 to − 1.9]
PSD (dB)	2.7 [2–5.9]	2.7 [1.9–8.7]	2.8 [2.2–4.5]	2.4 [1.9–8.9]	2.6 [1.6–7.1]	3.3 [1.9–6.6]
Pattern electroretinogram (P-ERG)
Amplitude Amp-p50 (μV)	1.7 [0.8–2.1]	1.1 [0.7–1.9]	1.7 [0.8–2.1]	1.1 [0.7–2.1]	1.6 [1–2.1]	1.2 [0.6–1.9]
Latency Lat-p50 (msec)	56.5 [53–61]	57 [54–59.5]	57 [54–61]	59 [56–60]	55 [52–61]	55 [52–59]
Amplitude Amp-n95 (μV)	2.7 [1.6–3.6]	2.7 [1.4–3.8]	2.6 [1.4–3.5]	2.6 [1.5–3.4]	2.7 [1.9–3.8]	3.5 [1.3–5]
Latency Lat-n95 (msec)	102.5 [98–107.5]	100 [96.5–107.5]	102 [96–107]	100 [96–107]	103 [98–108]	100 [97–109]
Quality of life (NEI-VFQ25)
General health (GH) (score)	50 [50–75]		50		50 [50–75]
General vision (GV) (score)	60 [60–60]		60 [40–60]		60 [60–60]
Total mean (score)	65 [60–75]		63.1 [57.5–73.8]		65 [60–75]

All values are expressed as median [IQR].